2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
Zhao J, Krishnamurti U, Zhang C, Meisel J, Wei Z, Suo A, Aneja R, Li Z, Li X. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology - Research And Practice 2020, 216: 153155. PMID: 32871536, DOI: 10.1016/j.prp.2020.153155.Peer-Reviewed Original ResearchConceptsHigh HER2/CEP17 ratioHER2/CEP17 ratioTumor responseBreast cancer casesNeoadjuvant HER2CEP17 ratioNeoadjuvant chemotherapyIHC 3Breast cancerCancer casesRCB II/IIIHER2-positive breast cancerHER2 IHC 3Complete pathologic responseResidual cancer burdenSmaller tumor sizePositive breast cancerLow nuclear gradeHER2 copy numberHigh Ki67Pathologic responseCancer burdenExcisional specimensPositive cancersTumor size
2019
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer
Meisel J, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer 2019, 20: 19-24. PMID: 31806448, DOI: 10.1016/j.clbc.2019.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreastBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantDNA Copy Number VariationsDrug Resistance, NeoplasmFeasibility StudiesFemaleHumansLymphocytes, Tumor-InfiltratingMastectomyMiddle AgedNeoadjuvant TherapyPredictive Value of TestsProgression-Free SurvivalReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTumor BurdenConceptsTumor-infiltrating lymphocytesHER2-positive breast cancerNeoadjuvant therapyHER2/CEP17 ratioBreast cancerClinicopathologic featuresTumor sizeEstrogen receptorKi-67High HER2/CEP17 ratioCEP17 ratioHER2 immunohistochemistry 3Pathologic complete responseProgesterone receptor expressionSmaller tumor sizeBreast cancer responseHigh Ki-67Low estrogen receptorHER2 copy numberRCB-IIPatient ageClinicopathologic factorsComplete responseInitial biopsyExcisional specimens
2017
New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
Li X, Oprea-Ilies G, Krishnamurti U. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. Archives Of Pathology & Laboratory Medicine 2017, 141: 490-498. PMID: 28353377, DOI: 10.5858/arpa.2016-0288-sa.Peer-Reviewed Original ResearchConceptsBreast cancerDaily practiceBreast specimensTriple-negative breast cancerDistinct biological subsetsHER2/neu gene amplificationTumor-infiltrating lymphocytesRadioactive seed localizationAppropriate treatment groupsNovel clinical practicesNeu gene amplificationNeoadjuvant treatmentPathologic evaluationHistopathologic parametersTreatment groupsClinical practiceTherapeutic utilityBiological subsetsCancerMolecular classificationBest treatmentPathologyNew guidelinesSeed localizationGene amplification
2016
Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Li X, Krishnamurti U, Bhattarai S, Klimov S, Reid M, O’Regan R, Aneja R. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. American Journal Of Clinical Pathology 2016, 145: 871-878. PMID: 27298399, DOI: 10.1093/ajcp/aqw045.Peer-Reviewed Original ResearchConceptsPathologic complete responseNeoadjuvant chemotherapyEstrogen receptorComplete responseLuminal subtypeProgesterone receptorBreast cancerTriple-negative breast cancer subtypeNottingham grade 3Stromal lymphocytic infiltrationNegative breast cancer subtypeBreast cancer patientsBreast cancer subtypesHigh mitotic countPR negativityHER2 positivityOverall cohortLymphocytic infiltrationTNBC subtypesCancer patientsHER2 statusPathologic parametersKi67 indexNuclear gradeClinical data